Olumiant Therapeutic Indications:
Rheumatoid Arthritis:
Olumiant is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs. Olumiant may be used as monotherapy or in combination with methotrexate.
Atopic Dermatitis:
Olumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.
Alopecia areata:
Olumiant is indicated for the treatment of severe alopecia areata in adult patients.

For full information please see the Israeli MOH approved PI.

Important safety information³

Olumiant has a balanced safety profile in RA.11 The very common side effects of Olumiant in RA are upper respiratory tract infections and hypercholesterolaemia. The common side effects are herpes zoster, herpes simplex, gastroenteritis, urinary tract infections, pneumonia, thrombocytosis >600 x 109 cells/L, headache, nausea, abdominal pain, alanine aminotransferase increased ≥3x upper limit of normal and rash.³

*Quote is created based on outcome of the ‘RA Matters’ survey of 1,231 people diagnosed with RA from France, Germany, Italy, the Netherlands, Sweden, the United Kingdom and Canada. The survey explored the outcomes and quality-of-life related areas that are most important, relevant and impactful to patients’ lives.

Abbreviations

ADA, adalimumab; AE, adverse event; IR, inadequate response; LS, least squares; MTX, methotrexate; ORBIT, Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy; PBO, placebo; RA, rheumatoid arthritis; VAS, visual analogue scale.

---

References:

1. Taylor PC, et al. N Engl J Med 2017;376:652–62 (PLUS SUPPLEMENTARY).
2. Caporali R, et al. Poster presented at EULAR 2022, POS0701.
3. Olumiant Prescribing information as approved by the Israeli MOH.
4. Taylor PC, et al. Ann Rheum Dis 2022;81:335–43 (PLUS SUPPLEMENTARY).
5. Alten R, et al. Rheumatol Ther 2022;1–21. doi: 10.1007/s40744-022-00500-6. Online ahead of print.
6. Alten R, et al. Poster presented at EULAR 2022. Poster POS0666.
7. Guidelli GM, et al. Clin Exp Rheumatol 2021;39:868–73.
8. Hernández-Cruz B, et al. Rheumatol Ther 2022;9:589–608.
9. Taylor PC, et al. Rheumatol Int 2016;36:685–95.
10. Alten R, et al. Rheumatol Ther 2019;6:587–97.
11. Genovese MC, et al. Lancet Rheumatol 2020;2:e347–57.
12. Taylor PC, et al. J Clin Med. 2019 Jun 12;8(6):831